Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official and paediatric dosages, pregnancy and breastfeeding guidance, and NHS pharmacy opening hours — all in one place.
Skyrizi contains the active substance risankizumab.
Skyrizi is used to treat plaque psoriasis in children and adolescents from 6 to less than 18 years of age.
How Skyrizi works This medicine works by stopping a protein in the body called ‘IL-23’, which causes inflammation. Skyrizi reduces inflammation and can therefore help reduce symptoms of plaque psoriasis such as burning, itching, pain, redness, and scaling.
Do not use Skyrizi • if you are allergic to risankizumab or any of the other ingredients of this medicine (listed in section 6).
• if you have an infection, including active tuberculosis, which your doctor thinks is important.
Warnings and precautions Talk to your doctor, pharmacist or nurse before and during the use of Skyrizi:
• if you currently have an infection or if you have an infection that keeps coming back.
• if you have tuberculosis (TB).
• if you have recently received or plan to receive an immunisation (vaccine). You should not be given certain types of vaccines while using Skyrizi.
It is important to keep a record of the batch number of your Skyrizi.
Every time you get a new pack of Skyrizi, note down the date and the batch number (which is on the packaging after “Lot”) and keep this information in a safe place.
Serious allergic reactions
Skyrizi can cause serious side effects, including serious allergic reactions (‘anaphylaxis’).
Tell your doctor or seek medical help immediately if you notice any signs of an allergic reaction while you are taking Skyrizi such as:
• difficulty breathing or swallowing
• swelling of the face, lips, tongue or throat
• low blood pressure, which can cause dizziness or light-headedness
• severe itching of the skin, with a red rash or raised bumps
Children and adolescents Skyrizi is not recommended for children under 6 years of age.
Other medicines and Skyrizi Tell your doctor, pharmacist or nurse:
• if you are using, have recently used or might use any other medicines.
• if you have recently had or are going to have a vaccination. You should not be given certain types of vaccines while using Skyrizi.
If you are not sure, talk to your doctor, pharmacist or nurse before and during the use of Skyrizi.
Pregnancy, contraception and breast-feeding If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. This is because it is not known how this medicine will affect the baby.
If you can become pregnant, you should use contraception while using this medicine and for at least 21 weeks after your last dose of Skyrizi.
If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.
Driving and using machines Skyrizi is not likely to affect your driving and use of machines.
Skyrizi contains polysorbate and sodium This medicine contains 0.07 mg of polysorbate 20 in each 55 mg dose. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.
This medicine contains less than 1 mmol sodium (23 mg) per pre-filled syringe, that is to say essentially ‘sodium-free’.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
This medicine is given as an injection under your skin (called a ‘subcutaneous injection’).
How much Skyrizi to use Age and body weight
Children and adolescents 6 to less than 18 years of age weighing less than 40 kg
How much and how often to take?
Each dose is 55 mg given as a single injection.
After the first dose, you will have the next dose 4 weeks later, and then every 12 weeks.
Age and body weight
Children and adolescents 6 to less than 18 years of age weighing at least 40 kg
How much and how often to take?
Each dose is 150 mg given as a single 150 mg injection.
A 150 mg pre-filled pen or 150 mg pre-filled syringe is available.
After the first dose, you will have the next dose 4 weeks later, and then every 12 weeks.
You and your doctor, pharmacist or nurse will decide if you should inject this medicine yourself. Do not inject yourself with this medicine unless you have been trained by your doctor, pharmacist or nurse. A caregiver may also give your injection after they have been trained.
Read section 7 ‘Instructions for use’ at the end of this leaflet before injecting Skyrizi.
If you use more Skyrizi than you should If you have used more Skyrizi than you should or the dose has been given sooner than prescribed, talk to your doctor.
If you forget to use Skyrizi If you forget to use Skyrizi, inject a dose as soon as you remember. Talk to your doctor if you are not sure what to do.
If you stop using Skyrizi Do not stop using Skyrizi without talking to your doctor first. If you stop treatment, your symptoms may come back.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects Allergic reactions – these may need urgent treatment. Tell your doctor or get emergency medical help straight away if you notice any of the following signs:
Serious allergic reactions (‘anaphylaxis’) are rare in people taking Skyrizi (may affect up to 1 in a 1 000 people). Signs include:
• difficulty breathing or swallowing
• swelling of the face, lips, tongue or throat
• low blood pressure, which can cause dizziness or light-headedness
Talk to your doctor or get medical help immediately if you have the following symptoms.
Symptoms of a serious infection such as:
• fever, flu-like symptoms, night sweats
• feeling tired or short of breath, cough which will not go away
• warm, red and painful skin, or a painful skin rash with blisters
Your doctor will decide if you can keep using Skyrizi.
Other side effects Tell your doctor, pharmacist or nurse if you get any of the following side effects.
Very common: may affect more than 1 in 10 people
• upper respiratory infections with symptoms such as sore throat and stuffy nose
Common: may affect up to 1 in 10 people
• feeling tired
• fungal skin infection
• injection site reactions (such as redness or pain)
• itching
• headache
• rash
• eczema
Uncommon: may affect up to 1 in 100 people
• small raised red bumps on the skin
• hives (urticaria)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the syringe label and outer carton after ‘EXP’.
Store in a refrigerator (2°C - 8°C). Do not freeze.
Keep the pre-filled syringe in the outer carton in order to protect from light.
If needed, you may also store the pre-filled syringe out of the refrigerator (up to a maximum of 25°C) for up to 24 hours in the original carton to protect from light.
Do not use this medicine if the liquid is cloudy or contains flakes or large particles.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Skyrizi contains • The active substance is risankizumab. Each pre-filled syringe contains 55 mg of risankizumab in 0.37 mL solution.
• The other ingredients are sodium acetate trihydrate, acetic acid, trehalose dihydrate, polysorbate 20 and water for injections. See section 2 “Skyrizi contains polysorbate and sodium”.
What Skyrizi looks like and contents of the pack Skyrizi is a clear and colourless to yellow liquid in a pre-filled syringe with needle guard. The liquid may contain tiny white or clear particles.
Each pack contains 1 pre-filled syringe.
Marketing Authorisation Holder AbbVie Ltd
Maidenhead
SL6 4UB
UK
Tel: +44 (0)1628 561090 Manufacturer AbbVie S.r.l.
S.R. 148 Pontina
Km 52 SNC
04011 Campoverde di Aprilia (LT)
Italy
or
AbbVie Biotechnology GmbH
Knollstrasse
67061 Ludwigshafen
Germany
This leaflet was last revised in 05/2026
To listen to or request a copy of this leaflet in Braille, large print or audio, please contact the Marketing Authorisation Holder.
Skyrizi 55 mg solution for injection in pre-filled syringe comes as solution containing 55 mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Skyrizi 55 mg solution for injection in pre-filled syringe is risankizumab.
Medicines with the same active substance include: Skyrizi 150 mg solution for injection in pre-filled pen, Skyrizi 150 mg solution for injection in pre-filled syringe, Skyrizi 180 mg solution for injection in cartridge, Skyrizi 360 mg solution for injection in cartridge, Skyrizi 600 mg concentrate for solution for infusion. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Skyrizi 55 mg solution for injection in pre-filled syringe, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Ask anything about Skyrizi 55 mg solution for injection in pre-filled syringe. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.